New insights into the links between anti-diabetes drugs and gut microbiota

Endocrine Connections

Yanting Yuan¹  Ji Zhou¹  Guohui Jiang¹  Ruixin Hu¹  Lixia Ji¹  Chaolong Liu¹ 

[1] School of pharmacy, Qing Dao University, Qingdao, China;

关键词: gut microbiota;    leaky gut;    functional pancreatic β-cells;    short-chain fatty acids (scfas);    anti-diabetes drugs;    type 2 diabetes mellitus (t2dm);   

DOI  :  https://doi.org/10.1530/EC-20-0431

来源: DOAJ

【 摘 要 】

In patients with type 2 diabetes mellitus (T2DM), the intestina l flora is out of balance and accompanied by leaky gut. The flora is characterized by an incre ase in mucus-degrading bacteria and a decrease in fiber-degrading bacteria. Short-chain fatty acids (SCFAs), as the major fiber-degrading bacteria fermentation, not only amelio rate the leaky gut, but also activate GPR43 to increase the mass of functional pancreatic β-cells and exert anti-inflammation effect. At present, the gut microbiota is considered as the potential target for anti-diabetes drugs, and how to reverse the imbalance of gu t microbiota has become a therapeutic strategy for T2DM. This review briefly summarizes the drugs or compounds that have direct or potential therapeutic effects on T 2DM by modulating the gut microbiota, including biguanides, isoquinoline alkaloids, stilbene and C7N-aminocyclic alcohols.

【 授权许可】

Unknown